Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-FIX, First In Vivo Protein Replacement Platform Program For Treatment Of Hemophilia B

Study, Scheduled to Begin in 2016, Will Represent First Clinical Application of In Vivo Genome Editing RICHMOND, Calif., Dec. 1, 2015 -- (Healthcare Sales & Marketing Network) -- Sangamo BioSciences, Inc. (SGMO), the leader in therapeutic genome editin... Biopharmaceuticals, FDASangamo BioSciences, SB-FIX, hemophilia B, genome editing, IVPRP
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news